Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al. · Science Translational Medicine · 2011 · 3.6K citations · Full text

Medicine, Genetics, Oncology +17

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Donavan T. Cheng, Talia Mitchell, Ahmet Zehir et al. · Journal of Molecular Diagnostics · 2015 · 2.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

RET, ROS1 and ALK fusions in lung cancer

Kengo Takeuchi, Manabu Soda, Yuki Togashi et al. · Nature Medicine · 2012 · 1.3K citations

Medicine, Genetics, Oncology +14

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +10